Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart Cafraglutide cardiovascular outcomes study in adults with ASCVD and overweight or obesity
jRCT2061250036Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Jul 2025
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, Overweight and obesity comparing Maridebart Cafraglutide with Placebo (2 arms). Primary endpoints: Time to first occurrence of 3-point major adverse cardiovascular events and Time to first occurrence of 5-point major adverse cardiovascular events. Started Jul 2025; status: recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
atherosclerotic diseaseOverweightobesity
Beyond the preview
Go deeper on jRCT2061250036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250036.